227 related articles for article (PubMed ID: 35241549)
21. Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab.
Minohara K; Matoba T; Kawakita D; Takano G; Oguri K; Murashima A; Nakai K; Iwaki S; Hojo W; Matsumura A; Ozaki S; Ozawa T; Harata I; Tanaka N; Maseki S; Tsuge H; Imaizumi S; Mitsuya S; Moribe K; Esaki S; Iwasaki S
Sci Rep; 2021 Aug; 11(1):16992. PubMed ID: 34417539
[TBL] [Abstract][Full Text] [Related]
22. Examining the Efficacy of Nivolumab for Gastric Cancer Focusing on Using an Inflammation-based Prognostic Score: A Multicenter Retrospective Study.
Nakazawa N; Sohda M; Tateno K; Watanabe T; Kimura A; Kogure N; Hosaka H; Naganuma A; Sekiguchi M; Saito K; Ogata K; Sano A; Sakai M; Ogawa H; Shirabe K; Saeki H
Anticancer Res; 2023 Feb; 43(2):927-934. PubMed ID: 36697068
[TBL] [Abstract][Full Text] [Related]
23. Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Wada A; Enokida T; Okano S; Sato M; Tanaka H; Ueda Y; Fujisawa T; Takeshita N; Tanaka N; Tahara M
Eur J Cancer; 2023 May; 184():30-38. PubMed ID: 36898232
[TBL] [Abstract][Full Text] [Related]
24. Site of distant metastasis affects the prognosis with recurrent/metastatic head and neck squamous cell carcinoma patients treated with Nivolumab.
Hoshi Y; Shirakura S; Yamada M; Sugiyama T; Koide N; Tamii S; Kamata K; Yokomura M; Osaki S; Ohno T; Yagihara K; Hara H; Beppu T
Int J Clin Oncol; 2023 Sep; 28(9):1139-1146. PubMed ID: 37421478
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of nivolumab as second line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a national DAHANCA cohort study.
Søby S; Gothelf A; Gyldenkerne N; Bentzen J; Nowicka-Matus K; Tramm T; Eriksen JG
Acta Oncol; 2022 Aug; 61(8):972-978. PubMed ID: 35913523
[TBL] [Abstract][Full Text] [Related]
26. Age-based efficacy and safety of nivolumab for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter retrospective study.
Kondo T; Okamoto I; Sato H; Koyama N; Fushimi C; Okada T; Masubuchi T; Miura K; Matsuki T; Yamashita T; Omura G; Takahashi H; Tsukahara K
Asia Pac J Clin Oncol; 2020 Dec; 16(6):340-347. PubMed ID: 32573033
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer - a retrospective multicentre study.
Okamoto I; Sato H; Kondo T; Koyama N; Fushimi C; Okada T; Miura K; Matsuki T; Yamashita T; Omura G; Tsukahara K
Acta Otolaryngol; 2019 Oct; 139(10):918-925. PubMed ID: 31460818
[No Abstract] [Full Text] [Related]
28. Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
Economopoulou P; Kotsantis I; Papaxoinis G; Gavrielatou N; Anastasiou M; Pantazopoulos A; Kavourakis G; Gkolfinopoulos S; Panayiotides I; Delides A; Psyrri A
Oral Oncol; 2020 Dec; 111():105013. PubMed ID: 32977184
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
[TBL] [Abstract][Full Text] [Related]
30. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab.
Roussel E; Kinget L; Verbiest A; Debruyne PR; Baldewijns M; Van Poppel H; Albersen M; Beuselinck B
Urol Oncol; 2021 Apr; 39(4):239.e17-239.e25. PubMed ID: 33485762
[TBL] [Abstract][Full Text] [Related]
31. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Docampo LCI; Haddad R; Rordorf T; Kiyota N; Tahara M; Lynch M; Jayaprakash V; Li L; Gillison ML
Oral Oncol; 2018 Jun; 81():45-51. PubMed ID: 29884413
[TBL] [Abstract][Full Text] [Related]
32. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
Ferris RL; Licitra L; Fayette J; Even C; Blumenschein G; Harrington KJ; Guigay J; Vokes EE; Saba NF; Haddad R; Ramkumar S; Russell J; Brossart P; Tahara M; Colevas AD; Concha-Benavente F; Lynch M; Li L; Gillison ML
Clin Cancer Res; 2019 Sep; 25(17):5221-5230. PubMed ID: 31239321
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.
Haddad R; Cohen EEW; Venkatachalam M; Young K; Singh P; Shaw JW; Korytowsky B; Abraham P; Harrington KJ
J Med Econ; 2020 May; 23(5):442-447. PubMed ID: 31928375
[No Abstract] [Full Text] [Related]
34. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab.
Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
Int J Clin Oncol; 2020 Jan; 25(1):135-144. PubMed ID: 31512006
[TBL] [Abstract][Full Text] [Related]
35. [Neutrophil-to-Lymphocyte Ratio(NLR)as a Predictive Indicator of the Response to Nivolumab in Patients with Oral Squamous Cell Carcinoma].
Tachinami H; Tomihara K; Ikeda A; Sekido K; Sakurai K; Imaue S; Fujiwara K; Hayashi R; Noguchi M
Gan To Kagaku Ryoho; 2021 Dec; 48(12):1485-1490. PubMed ID: 34911916
[TBL] [Abstract][Full Text] [Related]
36. Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma.
Inoue H; Yokota T; Hamauchi S; Onozawa Y; Kawakami T; Shirasu H; Notsu A; Yasui H; Onitsuka T
Auris Nasus Larynx; 2020 Aug; 47(4):650-657. PubMed ID: 32035695
[TBL] [Abstract][Full Text] [Related]
37. Inflammation and malnutrition as markers of poor outcomes in head and neck cancer patients treated with nivolumab.
Arihara Y; Takada K; Murase K; Kawamura K; Kakiuchi A; Kurose M; Sasaki T; Ogi K; Yamazaki M; Miyazaki A; Kato J; Takano K
Acta Otolaryngol; 2023 Aug; 143(8):714-720. PubMed ID: 37537940
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of chemotherapy after progression with nivolumab in squamous cell carcinoma of the head and neck.
Suzuki S; Toyoma S; Tomizawa H; Yamada T; Iikawa N; Shiina K; Saito H; Koizumi K; Kawasaki Y; Yamada T
Auris Nasus Larynx; 2020 Jun; 47(3):485-488. PubMed ID: 31248647
[TBL] [Abstract][Full Text] [Related]
39. Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients.
Chalker C; Voutsinas JM; Wu QV; Santana-Davila R; Hwang V; Baik CS; Lee S; Barber B; Futran ND; Houlton JJ; Laramore GE; Liao JJ; Parvathaneni U; Martins RG; Eaton KD; Rodriguez CP
Cancer Med; 2022 Nov; 11(22):4104-4111. PubMed ID: 35349227
[TBL] [Abstract][Full Text] [Related]
40. Nivolumab in squamous cell carcinoma of the head and neck.
Specenier P
Expert Rev Anticancer Ther; 2018 May; 18(5):409-420. PubMed ID: 29560755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
